Month: September 2021

Sep 04 2021

Uncategorized

FDA approves twice-yearly schizophrenia treatment – Healio

by Clinical Editor

No Comments

FDA approves twice-yearly schizophrenia treatment  Healio

Sep 04 2021

Uncategorized

FDA approves twice yearly injection for treatment for adults with schizophrenia

by Clinical Editor

No Comments

USA: The U.S. Food and Drug Administration (FDA) has approved Invega Hafyera (paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults.

Sep 04 2021

Uncategorized

When Do Schizophrenia Symptoms Start?

by Clinical Editor

No Comments

It’s rare for schizophrenia to appear before 13 or after 40, but it does happen. Here’s when most people develop it and the signs to look out for.

Sep 04 2021

Uncategorized

First and Only Twice-Yearly Treatment for Schizophrenia Receives FDA Approval

by Clinical Editor

No Comments

The one-of-its-kind 6-month paliperidone palmitate treatment for schizophrenia has received FDA approval. The US Food and Drug Administration (FDA) has approved Janssen Pharmaceutical’s long-acting …

Sep 04 2021

Uncategorized

FDA nod for Janssen schizophrenia treatment Invega Hafyera

by Clinical Editor

No Comments

The US Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate) for the treatment of schizophrenia in adults. The FDA approval …

Sep 04 2021

Uncategorized

FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia

by Clinical Editor

No Comments

The FDA has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera) for adults with schizophrenia.

Sep 03 2021

Uncategorized

FDA nod for Janssen schizophrenia treatment Invega Hafyera

by Clinical Editor

No Comments

The US Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate) for the treatment of schizophrenia in adults. The FDA approval …

Sep 03 2021

Uncategorized

FDA approves twice yearly injection for treatment for adults with schizophrenia

by Clinical Editor

No Comments

USA: The U.S. Food and Drug Administration (FDA) has approved Invega Hafyera (paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults.

Sep 03 2021

Uncategorized

First and Only Twice-Yearly Treatment for Schizophrenia Receives FDA Approval

by Clinical Editor

No Comments

The one-of-its-kind 6-month paliperidone palmitate treatment for schizophrenia has received FDA approval. The US Food and Drug Administration (FDA) has approved Janssen Pharmaceutical’s long-acting …

Sep 03 2021

Uncategorized

New treatment option for schizophrenia – Reagila(R) – listed on PBS this week

by Clinical Editor

No Comments

Adults living with schizophrenia will have access to a new treatment option with Reagila(R) (cariprazine) now reimbursed on the Pharmaceutical Benefits Scheme from 1 September, 2021.1 – There …